echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Clinical trial found that interferon does not help hospitalized adults with new coronary pneumonia

    Clinical trial found that interferon does not help hospitalized adults with new coronary pneumonia

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Color scanning electron microscope image (red) of human cells severely infected with SARS-CoV-2 virus particles
    .

    A clinical trial found that among hospitalized adults suffering from COVID-19 pneumonia, treatment with the immunomodulator interferon β1a plus the antiviral drug remdesivir is not superior to the treatment of remdesivir alone
    .
    In addition, in a group of patients requiring high-flow oxygen, the researchers found that interferon β1a was associated with more adverse events and worse outcomes
    .
    These findings are published today (October 18, 2021 ) in the journal The Lancet Respiratory Medicine
    .

    This study is called Adaptive COVID-19 Therapy Trial 3 (ACTT-3) and will be conducted from August 5, 2020 to December 21, 2020
    .
    It is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health
    .

    The amino acid sequence of interferon β1a is the same as that of a natural protein called interferon-β, which belongs to a class of proteins called type 1 interferons
    .
    Infected cells usually produce type 1 interferon, which helps the immune system fight pathogens, especially viruses
    .
    Interferon has anti-viral and anti-inflammatory properties
    .

    Laboratory studies have shown that after infection with the SARS-CoV-2 virus that causes COVID-19, the normal type 1 interferon response is suppressed
    .
    In addition, previous studies of COVID-19 hospitalized patients have shown that many patients produce less interferon when responding to SARS-CoV-2 infection, which is related to more serious diseases
    .
    Other laboratory studies and clinical data support the hypothesis that interferon β1a treatment may improve the health outcomes of COVID-19 patients
    .

    However, the ACTT-3 researchers finally found that in COVID-19 hospitalized adult patients, the clinical benefits of interferon β1a plus redecivir were not relevant compared with redecivir alone
    .
    For participants who received interferon β1a + remdesivir, the main outcome (recovery time) was the same as that of participants who received remdesivir alone, with a median of 5 days
    .
    The likelihood of clinical improvement on the 15th day of the two groups was also similar
    .

    In this study, Remdesivir is still used as an active control because the first iteration of the ACTT trial found that antiviral drugs are better than placebo in reducing the recovery time of COVID-19 hospitalized patients
    .

    The ACTT-3 research team recruited 969 adults in 63 locations in the United States, Japan, Mexico, Singapore, and South Korea
    .
    60% of the patients were white, 17% were black, 9% were Asian, 1% were American Indian or Alaska Native, and 32% were Hispanic or Latino
    .
    Participants were randomly assigned at a ratio of 1:1 and received interferon β1a + remdesivir or placebo + remdesivir
    .
    Until the end of the trial, the participants and the research team did not know who received which treatment
    .

    On September 4, 2020, the study was modified to stop including patients with severe COVID-19 who require high-flow oxygen, and exclude those who require non-invasive or invasive mechanical ventilation
    .
    These changes are noted by the Research Data and Safety Monitoring Board (DSMB) that among participants who require high-flow oxygen at the time of registration, those who received interferon β1a had a higher incidence of serious adverse events than those who did not receive interferon β1a.
    , Especially the deterioration of respiratory conditions
    .
    The ACTT-3 researchers speculated that interferon might increase the inflammatory response, leading to more severe respiratory diseases in these participants
    .
    However, the researchers noted that this worse result may be affected by the baseline imbalance between the interferon and the control group
    .

    "Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalized adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial" 18 October 2021, The Lancet Respiratory Medicine .

    DOI: 10.
    1016/S2213 -2600(21)00412-4

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.